Use of genomic markers to risk stratify men with prostate cancer
New genomic biomarkers are being developed to refine the risk for men with prostate cancer, but for healthcare professionals to believe in them, they must be both valid and of clinical utility. John Davis reviews three of these biomarkers, providing advice on how to interpret results and make decisions.
Source: Trends in Urology, Gynaecology and Sexual Health - Category: OBGYN Authors: John W. Davis Tags: Prostate Disease Source Type: research